5 Key Takeaways

• 1

  The FDA has granted De Novo marketing authorization to Avulux for its precision light-filtering lenses for migraine management.

• 2

  Avulux lenses are indicated for patients aged 12 and older with episodic migraine and are designed to block specific light wavelengths.

• 3

  The lenses aim to reduce light sensitivity impact without replacing standard migraine treatments, which patients should continue.

• 4

  Avulux lenses have been dispensed to over 50,000 users and are available through a network of more than 1,400 eye care providers.

• 5

  The authorization creates a new FDA classification for precision optical filters addressing migraine-associated light sensitivity.